The following list of cancer immunotherapies are available for licensing under U.S. Patent Publication No.: 20220370499.

Immunotherapies for Targeting of Tumor Vasculature

Abstract
Disclosed are novel means, protocols, and compositions of matter for creating targeted immune responses and/or induction of immunological memory towards the tumor vasculature. In one embodiment pluripotent stem cells are transfected with one or more genes capable of eliciting immunity, induced to differentiate into endothelial-like cells which resemble the tumor endothelial cells, and utilized as a vaccine. In some embodiment’s genes are engineered under control of specific promoters to allow for various specificities of activity. In one specific embodiment pluripotent stem cells engineered to endow properties capable of inducing expression of the α-Gal epitope (Galα1,3Galα1,4GlcNAc-R). Addition of adjuvants to enhance antigen presentation of the vaccine composition, as well as means of stimulating systemic enhancement of circulating endothelial specific T cells are also disclosed.







Melanoma is a dangerous type of skin cancer that develops from melanocytes, the cells that produce melanin, the pigment that gives skin and hair their color.

Upfront Fee Annual Minimum Royalty Phase 1 IND Phase 2 IND Phase 3 IND BLA Royalty
$50,000 $10,000 $100,000 $250,000 $500,000 $1,000,000 6%

Juvenile melanoma, also known as melanoma in children, is a rare but common skin cancer in children.

Upfront Fee Annual Minimum Royalty Phase 1 IND Phase 2 IND Phase 3 IND BLA Royalty
$50,000 $10,000 $100,000 $250,000 $500,000 $1,000,000 6%

Lentigo maligna melanoma is a type of skin cancer that develops from a lentigo maligna, a precancerous condition.

Upfront Fee Annual Minimum Royalty Phase 1 IND Phase 2 IND Phase 3 IND BLA Royalty
$50,000 $10,000 $100,000 $250,000 $500,000 $1,000,000 6%

Malignant melanoma, also known as melanoma, is a dangerous type of skin cancer that can develop from melanocytes, the cells that produce melanin and give skin its color.

Upfront Fee Annual Minimum Royalty Phase 1 IND Phase 2 IND Phase 3 IND BLA Royalty
$50,000 $10,000 $100,000 $250,000 $500,000 $1,000,000 6%

Acral-lentiginous melanoma is a specific type of melanoma that appears on the palms of the hands, the soles of the feet, or under the nails.

Upfront Fee Annual Minimum Royalty Phase 1 IND Phase 2 IND Phase 3 IND BLA Royalty
$50,000 $10,000 $100,000 $250,000 $500,000 $1,000,000 6%

Amelanotic melanoma, these skin lesions lack melanin, the dark pigment that gives most moles and melanomas their color. Instead, amelanotic melanomas can be clear, white or skin-colored, sometimes with a slight pink, purple or red tint.

Upfront Fee Annual Minimum Royalty Phase 1 IND Phase 2 IND Phase 3 IND BLA Royalty
$50,000 $10,000 $100,000 $250,000 $500,000 $1,000,000 6%

Benign juvenile melanoma is an old term for a rare, noncancerous mole called a Spitz nevus.

Upfront Fee Annual Minimum Royalty Phase 1 IND Phase 2 IND Phase 3 IND BLA Royalty
$50,000 $10,000 $100,000 $250,000 $500,000 $1,000,000 6%

Nodular melanoma subungal melanoma is a rare and aggressive form of skin cancer that can appear as a nodule under the nail.

Upfront Fee Annual Minimum Royalty Phase 1 IND Phase 2 IND Phase 3 IND BLA Royalty
$50,000 $10,000 $100,000 $250,000 $500,000 $1,000,000 6%

Superficial spreading melanoma is a type of skin cancer that is the most common form of melanoma, accounting for 70–80% of cases.

Upfront Fee Annual Minimum Royalty Phase 1 IND Phase 2 IND Phase 3 IND BLA Royalty
$50,000 $10,000 $100,000 $250,000 $500,000 $1,000,000 6%